AI
ALGS icon

Atom Investors’s Aligos Therapeutics ALGS Stock Holding History

Atom Investors’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,367
Closed -$33.5K – 471
2024
Q1 		$33.5K Buy
+1,367
New +$27.2K ﹤0.01% 546
2022
Q3 		– Sell
-907
Closed -$27K – 279
2022
Q2 		$27K Buy
+907
New +$30.8K 0.01% 240

Other funds holding ALGS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Atom Investors's ALGS Position: Q2 2024 in Review

Atom Investors sold out of Aligos Therapeutics (ALGS) in Q2 2024, closing a stake of 1,367 shares — an estimated $33.5K sold.

Atom Investors first reported a position in ALGS in Q2 2022 and held it in 2 quarters. The position peaked at $33.5K in Q1 2024. 48 funds tracked by Wall St. Rank hold ALGS as of Q2 2024.

  • Atom Investors reported no remaining Aligos Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Atom Investors sold 1,367 Aligos Therapeutics shares in Q2 2024, an estimated $33.5K.
  • Atom Investors first reported a position in Aligos Therapeutics in Q2 2022 and held it in 2 quarters.
  • Atom Investors's Aligos Therapeutics position peaked at $33.5K in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2024.

Based on Atom Investors's 13F filing for Q2 2024, filed 14 Aug 2024.